Harvill will lead Avomeen’s day-to-day activities with an emphasis on continuing the company’s rapid growth achieved since its inception in 2010. High Street Capital is the majority shareholder of Avomeen following the company’s recapitalization at year-end 2016. Dr. Thanedar will continue to hold a minority interest and serve on the company’s Board of Directors. He will work closely with Harvill to ensure a smooth transition.
“Over the years, Avomeen has established itself as the go-to manufacturing problem-solving company, achieving great success under Shri’s leadership,” said Rob France, Principal of High Street Capital. “We are pleased to welcome Mark aboard to execute the next steps in Avomeen’s progression as a national leader in the custom product research & development space, and we look forward to reaching new heights as we pursue our aggressive growth goals in the years ahead.”
A native Michigander, Harvill has more than 20 years of experience in contract research organization management, most recently serving as the chief operating officer of Clinipace Worldwide in Morrisville, North Carolina. There he was responsible for leading global operations in North America, Latin America, Europe and Asia Pacific. Prior to Clinipace Harvill served as president and chief operating officer of Paragon Biomedical in Irvine, California. He also spent 12 years at STATPROBE in Ann Arbor as executive vice president.
“Avomeen is a thriving company, and I am excited to bring my knowledge and expertise in this industry to Ann Arbor,” Harvill said. “I’m proud to return to my home state of Michigan during a time of resurgence throughout the state, with the opportunity to guide Avomeen’s dedicated chemists and formulation developers to even greater success in product testing, development and analytical problem solving.”